PRDX6 Prevents NNMT Ubiquitination and Degradation as a Nonenzymatic Mechanism to Promote Ovarian Cancer Progression
Source abstract
Abstract
Abstract Cancer cells cope with oxidative stress for their proliferation and metastasis by equipping antioxidant systems, among which the antioxidant enzymes peroxiredoxins (PRDXs) play crucial roles. However, whether PRDXs exhibit nonenzymatic functions remains unclear. Here, it is shown that the 1‐cysteine PRDX (PRDX6) upregulates nicotinamide N‐methyltransferase (NNMT) to promote the growth and metastasis of ovarian cancer cells, independently of PRDX6's enzymatic activities. Mechanistically, PRDX6 interacts with NNMT to prevent its binding to the E3 ubiquitin ligase tripartite‐motif protein 56 (TRIM56), leading to the inhibition of NNMT ubiquitination at lysine 23 and 210 and suppression of subsequent proteasomal degradation. In addition, PRDX6‐mediated NNMT upregulation activates mitogen‐activated protein kinase (MAPK) signaling, thereby promoting the growth and metastasis of ovarian cancer cells. Notably, PRDX6 overexpression is associated with higher NNMT protein levels in human ovarian cancer tissues and is predictive of poor prognosis of ovarian cancer patients. Overall, the findings illustrate a critical oncogenic mechanism of the antioxidant enzyme PRDX6 in promoting ovarian cancer progression beyond its enzymatic mechanisms.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Redox biology and oxidative stress · RNA modifications and cancer · Metal-Catalyzed Oxygenation Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
West China School of Basic Medical Sciences & Forensic Medicine State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu 610041 P. R. China
Center for Reproductive Medicine Department of Gynecology and Obstetrics West China Second University Hospital Sichuan University Chengdu 610041 P. R. China
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University) Ministry of Education Chengdu 610041 P. R. China
References (57)
Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.3322/caac.2145610.3322/caac.21456 ↗
3. 10.1186/s13148-018-0602-010.1186/s13148-018-0602-0 ↗
4. 10.1136/bmj.m377310.1136/bmj.m3773 ↗
5. 10.1038/s41571-023-00819-110.1038/s41571-023-00819-1 ↗
6. 10.1016/j.molcel.2021.08.03110.1016/j.molcel.2021.08.031 ↗
7. 10.1016/j.cmet.2020.12.01510.1016/j.cmet.2020.12.015 ↗
8. 10.1007/s11684-020-0818-110.1007/s11684-020-0818-1 ↗
9. 10.1089/ars.2020.812310.1089/ars.2020.8123 ↗
10. 10.1038/s41580-018-0029-710.1038/s41580-018-0029-7 ↗
11. 10.1038/s41586-020-2183-210.1038/s41586-020-2183-2 ↗
12. 10.1038/s41586-018-0018-110.1038/s41586-018-0018-1 ↗
13. 10.1038/s41467-020-19263-110.1038/s41467-020-19263-1 ↗
14. 10.1038/s42255-021-00456-x10.1038/s42255-021-00456-x ↗
15. 10.1038/s41467-018-06841-710.1038/s41467-018-06841-7 ↗
16. 10.15252/embj.202211155010.15252/embj.2022111550 ↗
17. 10.1038/s42255-022-00708-410.1038/s42255-022-00708-4 ↗
18. 10.1038/s42255-021-00524-210.1038/s42255-021-00524-2 ↗
19. 10.1016/j.cmet.2023.03.01710.1016/j.cmet.2023.03.017 ↗
20. 10.1016/j.pharmthera.2016.03.01810.1016/j.pharmthera.2016.03.018 ↗
21. 10.1186/s12935-021-02064-x10.1186/s12935-021-02064-x ↗
22. 10.1089/ars.2017.716210.1089/ars.2017.7162 ↗
23. 10.1016/j.redox.2024.10333210.1016/j.redox.2024.103332 ↗
24. 10.1089/ars.2023.028710.1089/ars.2023.0287 ↗
25. 10.1074/jbc.M00507320010.1074/jbc.M005073200 ↗
26. 10.1038/s41401-019-0233-910.1038/s41401-019-0233-9 ↗
27. 10.1194/jlr.M06475810.1194/jlr.M064758 ↗
28. 10.1186/bcr178910.1186/bcr1789 ↗
29. 10.1016/j.redox.2020.10173710.1016/j.redox.2020.101737 ↗
30. 10.1016/j.freeradbiomed.2014.02.00110.1016/j.freeradbiomed.2014.02.001 ↗
31. 10.1194/jlr.M700299-JLR20010.1194/jlr.M700299-JLR200 ↗
32. 10.1016/j.redox.2021.10213010.1016/j.redox.2021.102130 ↗
33. 10.1002/jcp.2611410.1002/jcp.26114 ↗
34. 10.1158/1078-0432.CCR-16-132310.1158/1078-0432.CCR-16-1323 ↗
35. 10.1038/nchembio.120410.1038/nchembio.1204 ↗
36. 10.1016/j.canlet.2022.21588410.1016/j.canlet.2022.215884 ↗
37. 10.1016/j.ccell.2020.06.00110.1016/j.ccell.2020.06.001 ↗
38. 10.1016/j.biopha.2023.11489610.1016/j.biopha.2023.114896 ↗
39. 10.1016/j.cell.2011.03.05410.1016/j.cell.2011.03.054 ↗
40. 10.1016/j.molcel.2012.01.00110.1016/j.molcel.2012.01.001 ↗
41. 10.3109/07357907.2010.53505610.3109/07357907.2010.535056 ↗
42. 10.1371/journal.pone.009150810.1371/journal.pone.0091508 ↗
43. 10.1038/s41419-022-05267-w10.1038/s41419-022-05267-w ↗
44. 10.1038/ncomms444610.1038/ncomms4446 ↗
45. 10.1038/s41419-022-04713-z10.1038/s41419-022-04713-z ↗
46. 10.1016/j.drudis.2021.05.01110.1016/j.drudis.2021.05.011 ↗
47. 10.1016/j.molmet.2021.10116510.1016/j.molmet.2021.101165 ↗
48. 10.1038/s41698-024-00509-w10.1038/s41698-024-00509-w ↗
49. 10.1002/advs.20230590710.1002/advs.202305907 ↗
50. 10.1038/s41388-021-01838-x10.1038/s41388-021-01838-x ↗
51. 10.1080/01443615.2020.173289110.1080/01443615.2020.1732891 ↗
52. 10.1186/s12885-021-07785-w10.1186/s12885-021-07785-w ↗
53. 10.1158/1535-7163.MCT-22-027810.1158/1535-7163.MCT-22-0278 ↗
54. 10.1038/s41586-019-1173-810.1038/s41586-019-1173-8 ↗
55. 10.1080/15548627.2023.223904210.1080/15548627.2023.2239042 ↗
56. 10.1038/s41467-023-36708-510.1038/s41467-023-36708-5 ↗
57. 10.1038/s41467-024-49087-210.1038/s41467-024-49087-2 ↗